AASK Colhort Study

描述（由申请人提供）： 高血压肾病通常进展。AASK（非裔美国人肾脏疾病和高血压研究）队列研究的主要目的是前瞻性确定接受推荐降压治疗的非裔美国人高血压肾病患者的肾功能病程和肾脏疾病进展的风险因素。次要目的是确定心血管疾病的发生率并评估其风险因素。 AASK队列研究是一项前瞻性、观察性研究，是AASK试验的扩展。AASK试验测试了3种药物（雷米普利、美托洛尔和曲马多）作为初始降压治疗和2种血压控制水平对肾功能的影响。在1，094名试验参与者中，约有650至700名未达到终末期肾病（ESRD）的个体可能会入组队列研究。要研究的风险因素包括环境、遗传、生理和社会经济变量。主要肾脏结局是一种复合临床结局，定义为血清肌酐加倍、ESRD或死亡。向所有参与者提供高血压药物治疗，从血管紧张素转换酶抑制剂雷米普利开始。以这种方式，该研究直接控制了肾脏疾病进展的两个主要决定因素（高血压的治疗和肾脏保护性降压药物的使用）。队列研究的最短随访时间为5年（总计9 - 12年，包括AASK试验期）。 最终，来自AASK队列研究的数据应该增强我们对决定肾脏疾病进展的风险因素和过程的理解。这样的结果可能最终导致延迟或预防ESRD的新策略。

DESCRIPTION (provided by applicant): Hypertensive kidney disease commonly progresses. The primary objective of the AASK (African American Study of Kidney Disease and Hypertension) Cohort Study is to determine prospectively the course of kidney function and risk factors for kidney disease progression in African-Americans with hypertensive kidney disease who receive recommended antihypertensive therapy. A secondary objective is to determine the occurrence of cardiovascular disease and assess its risk factors. The AASK Cohort Study is a prospective, observational study that is an extension of the AASK trial. The AASK trial tested the effects on kidney function of 3 medications used as initial antihypertensive therapy (ramipril, metoprolol and amlodipine) and 2 levels of blood pressure control. Of the 1,094 trial participants, approximately 650 to 700 individuals who have not reached end stage renal disease (ESRD) will likely enroll in the Cohort Study. Risk factors to be studied include environmental, genetic, physiologic, and socio-economic variables. The primary renal outcome is a composite clinical outcome defined by doubling of serum creatinine, ESRD, or death. Medication treatment for hypertension, beginning with the angiotensin converting enzyme inhibitor ramipril, is offered to all participants. In this fashion, the study directly controls two of the major determinants of kidney disease progression (treatment of hypertension and use of reno-protective, antihypertensive medication). The minimum duration of follow-up in the Cohort Study is 5 years (total of 9 to 12 years, including the period of the AASK trial). Ultimately, data from the AASK Cohort Study should enhance our understanding of the risk factors and processes that determine the progression of kidney disease. Such results might eventually lead to new strategies that delay or prevent ESRD.